Introduction: R(+) and S(-) limonene are major compounds of M. spicata essential oil have been reported to be used in treatment due to their antimicrobial, anticancer, anti-angiogenic, anti- inflammatory and antioxidant effects and as well as in cosmetics and as sweetener in drinks (1). We aimed to design and characterize R(+) or S(-) limonene loaded nanoparticles (NPs) and investigate their in vivo anti-angiogenic and anti- inflammatory potentials.

Materials and Methods: Eudragit RS 100-based NPs were prepared by following the nanoprecipitation technique with some modifications (2). The in vivo anti-angiogenic and anti-inflammatory activities of R(+) and S(-) limonene NPs were evaluated by using in vivo CAM and HET-CAM assays respectively (3,4).

Results: According to the results, NPs at the concentration of 50 μg/pellet including R(+) limonene and S(-) limonene as 4 μg/pellet showed strong in vivo anti-angiogenic potentials with anti- angiogenic scores of 0.93 ± 0.1 and 0.74 ± 0.05 and no membrane irritation and embryotoxicity compared with (±)-Thalidomide (0.8 ± 0.05) (Figure 1). R(+) and S(-) limonene NPs also exhibited strong in vivo anti-inflammatory activities with 75.00 ± 12.50% and 80.00 ± 11.18% inhibition values compared with 81.25 ± 8.84%.